Table 1 Baseline characteristics of COPD cases.

From: A blood and bronchoalveolar lavage protein signature of rapid FEV1 decline in smoking-associated COPD

 

All (N = 45)

Greater decliners‡ (N = 14)

Lesser decliners (N = 31)

P-Value†

Age*

63.4 (± 7.75)

64.2 (± 6.24)

63.1 (± 8.41)

0.65

Currently Smoking*

15 (33.3%)

5 (35.7%)

10 (32.3%)

 > 0.99

BMI*

27.8 (± 4.91)

27.9 (± 3.67)

27.8 (± 5.43)

0.93

Sex (Male)

29 (64.4%)

12 (85.7%)

17 (54.8%)

0.09

Race (White / Other)

37/8 (82.2%)

12/2 (85.7%)

25/6 (80.6%)

 > 0.99

ICS use* (yes)

17 (37.8%)

3 (21.4%)

14 (45.2%)

0.18

FEV1* (% predicted)

75.6 (± 17.4)

84.2 (± 13.1)

71.1 (± 17.7)

0.017

FEV1/FVC*

0.58 (± 0.09)

0.60 (± 0.08)

0.57(± 0.10)

0.27

FEV1* (L)

2.27 (± 0.68)

2.63 (± 0.60)

2.11 (± 0.66)

0.015

Visit 5 FEV1 (L)

1.94 (± 0.67)

1.97 (± 0.67)

1.93 (± 0.68)

0.85

Time from baseline to Visit 5 (yrs)

6.31 (± 0.86)

6.25 (± 0.76)

6.33 (± 0.91)

0.79

Time from baseline to bronchoscopy (months)

20.3 (± 11.6)

20.4 (± 10.0)

20.3 (± 12.5)

0.96

∆FEV1 (mL/yr)

− 52.4 (± 43.3)

− 104.6 (± 32.0)

− 28.8 (± 21.5)

 
  1. Two-sample, two-tailed t-test or Fisher’s exact test were used to determine significant differences.
  2. *Demographic information from baseline visit (Visit 1).
  3. †P-values are associated with differences between greater decliner and lesser decliner groups.
  4. ‡Decline in FEV1 (mL/yr) ≥ 70 mL/year (see Methods).
Back to article page